Amylin Pharma (AMLN) Reports Q4 GAAP Loss of $3.15/Share
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q4 GAAP loss of $3.15, which does not compare to the analyst estimate of ($0.08). The company posted a loss per share of 13 cents during the same quarter last year. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $163.64 million.
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Largo restructures $82.2M in debt, extending maturity to 2030
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
